Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03785249 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Mirati Therapeutics.

Active
Registry status
Phase 1
Development phase
731
Enrollment target
20
Study locations

NCT03785249: Active Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Mirati Therapeutics.

NCT03785249 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is active but no longer recruiting, run by Mirati Therapeutics. The registered enrollment target is 731 participants, above the 240-participant average among 122 other Advanced Cancer trials with a reported enrollment target (205% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03785249, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by Mirati Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
731 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Primary Outcome

Number of participants with treatment related adverse events

Conditions Studied

Advanced Cancer Metastatic Cancer Malignant Neoplastic Disease

Interventions

  • DRUG Pembrolizumab
  • DRUG Cetuximab
  • DRUG Afatinib
  • DRUG MRTX849

Study Locations (20)

California

  • Local Institution - 001-840-B - Bellflower
  • Local Institution - 001-834 - Beverly Hills
  • Local Institution - 001-843 - Duarte
  • Local Institution - 001-850-K - Dublin
  • Local Institution - 001-851 - Fullerton
  • Local Institution - 001-840-C - Harbor City
  • Local Institution - 001-805 - La Jolla
  • Local Institution - 001-779 - Los Alamitos
  • Local Institution - 001-840 - Los Angeles
  • Local Institution - 001-578 - Los Angeles
  • Local Institution - 001-847 - Newport Beach
  • Local Institution - 001-850-B - Oakland
  • Local Institution - 001-803 - Orange
  • Local Institution - 001-850-C - Roseville
  • Local Institution - 001-850-J - Sacramento

Arizona

  • Local Institution - 001-821 - Phoenix
  • Local Institution - 001-873-A - Tucson
  • Local Institution - 001-873 - Tucson

Alabama

  • Local Institution - 001-826 - Birmingham

Alaska

  • Local Institution - 001-965 - Anchorage

Trial Details

FieldValue
Enrollment Target 731 participants
Start Date 2019-01-15
Est. Completion 2026-12-31
Phase Phase 1
Mirati Therapeutics

49 total trials

What the registry record for NCT03785249 still lists

NCT03785249 is an interventional study that assigns participants to a tested intervention. The registered 731 participants enrollment target is mid-sized for trials with a published cap, above the 240-participant average among 122 other Advanced Cancer trials with a reported enrollment target (205% higher).

The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03785249 names 20 study sites across 4 states, led by California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT03785249 about?

NCT03785249 is a clinical study titled "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1". This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

What is the current status of trial NCT03785249?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 731 participants. The study started on 2019-01-15. Estimated completion is 2026-12-31.

What conditions does trial NCT03785249 study?

This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease.

What interventions are being tested in trial NCT03785249?

The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), Afatinib (DRUG), MRTX849 (DRUG).

Who is sponsoring clinical trial NCT03785249?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03785249 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03785249's enrollment target sits among peer trials

731 4th of 122 higher than 119 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03232918 · 730 participants · Phase 4

    Oxytocin and Fetal Heart Rate Changes

  • NCT05548283 · 730 participants · Phase 4

    Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

  • NCT07312162 · 730 participants

    Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

  • NCT06216301 · 734 participants · Phase 3

    LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03785249, the US trial registry maintained by the National Library of Medicine. NCT03785249 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.